Laryngeal Cancer Therapeutics Market: Introduction

Laryngeal cancer can be defined as the rare cancer in which malignant cells grow in the voice box or the larynx. Larynx consists of three main parts that include glottis, supraglottis, and subglottis. Laryngeal cancer mainly begins in the glottis area of the larynx. Most laryngeal cancers begin as the flat, scale-like squamous cells lining the inner walls of the larynx.

Symptoms of laryngeal cancer include hoarseness, persistent cough, sore throat, difficulty or pain in swallowing, difficulty or noisy breathing, persistent bad breath, significant weight loss, and persistent ear pain. According to American Cancer Society, over 90% of the patients with stage 1 glottis cancer, survive for a period of more than five years. Furthermore, over 60% of the patients with stage 1 supraglottis cancer survive for a period of over five years.

Global Laryngeal Cancer Therapeutics Market: Competitive Landscape

Strong focus on enhancing product pipeline and significant alliances with other market players to launch advanced therapies for the treatment of laryngeal cancer, help the market players enhance their market presence. 

Need an Overview of the Report on Laryngeal Cancer Therapeutics Market? Ask for the Brochure here

Bristol-Myers Squibb Co.

The Squibb Corporation was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York. Bristol-Myers and Squibb merged in 1989. The company is engaged in development, manufacturing, and marketing of biopharmaceutical products globally. The biopharmaceuticals segment of the company is engaged in the development, discovery, licensing, marketing, and distribution of medicines for the treatment of serious diseases.

Eli Lilly and Co.

Established in 1876, Eli Lilly and Co., is engaged in development, manufacturing, and marketing of pharmaceutical products. The company operates its business through two business segments: Animal Health Products and Human Pharmaceutical Products. The company’s offerings include GEMZAR and ERBITUX.    

F. Hoffmann-La Roche Ltd

Founded in 1896, F. Hoffmann-La Roche Ltd develops in-vitro diagnostic products and drugs for the treatment of cancers. The company is an expert in providing transplantation products and medications in various specializations, including chronic diseases, infectious diseases, and microbiology. The company operates its business through two business segments: Diagnostics and Pharmaceuticals.                  

Laryngeal Cancer Therapeutics Market: Dynamics

Increasing Incidence of Tobacco Consumption

According to Centers for Disease Control and Prevention-CDC, the tobacco product consumption has been significantly rising in the U.S. Cigarette smoking is the leading cause of preventable disease and death in the United States, accounting for more than 480,000 deaths every year, or about 1 in 5 deaths. In 2017, 14 of every 100 U.S. adults aged 18 years or older (14.0%) currently* smoked cigarettes. This means an estimated 34.3 million adults in the United States currently smoke cigarettes.2 More than 16 million Americans live with a smoking-related disease.

Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “Laryngeal Cancer Therapeutics Market” here

Rising Prevalence of Laryngeal Cancer

According to American Cancer Society, the incidence of laryngeal cancer is around 3.6 people in 100,000 population per year in U.S. This estimated to over 13,365 new cases of laryngeal cancer in 2017. The new cases of laryngeal cancer in 2019 was estimated to be over 12,415 cases.

Significant Clinical Trial Failures

Laryngeal cancer is one of types of respiratory tract cancer after lung cancer. Significant efforts have been conducted for development of novel therapies to treat laryngeal cancer. However, the high costs involved in recruiting patients for clinical trials and the high cost of drugs poses a significant loss to the vendor in case of clinical trial failures. This is expected to hamper the market.

Global Laryngeal Cancer Therapeutics Market: Segmentation

The global laryngeal cancer therapeutics market can be segmented on the basis of:

  • Product Type
  • Route of Administration
  • End-user

Based on product type, the laryngeal cancer therapeutics market is divided into:

  • Biologics
  • Small Molecules

In terms of route of administration, the laryngeal cancer therapeutics market is bifurcated into:

  • Oral
  • Intravenous

Based on end-user, the laryngeal cancer therapeutics market is classified into:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Centers
  • Others

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Laryngeal Cancer Therapeutics Market

Pre Book